Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.

Sison EAR, Kurre P, Kim YM.

Pediatr Hematol Oncol. 2017 Sep - Oct;34(6-7):365-378. doi: 10.1080/08880018.2017.1395938. Epub 2017 Dec 6. Review.

2.

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26414. Epub 2017 Apr 14.

3.

Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.

Minus MB, Liu W, Vohidov F, Kasembeli MM, Long X, Krueger MJ, Stevens A, Kolosov MI, Tweardy DJ, Sison EA, Redell MS, Ball ZT.

Angew Chem Int Ed Engl. 2015 Oct 26;54(44):13085-9. doi: 10.1002/anie.201506889. Epub 2015 Sep 7.

4.

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.

Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P.

Oncotarget. 2015 Oct 13;6(31):30902-18. doi: 10.18632/oncotarget.5094.

5.

CNS prophylaxis in pediatric acute lymphoblastic leukemia.

Sison EA, Silverman LB.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):198-201. doi: 10.1182/asheducation-2014.1.198. Epub 2014 Nov 18. Review. No abstract available.

PMID:
25696855
6.
7.

Does hematopoietic stem cell transplantation benefit infants with acute leukemia?

Sison EA, Brown P.

Hematology Am Soc Hematol Educ Program. 2013;2013:601-4. doi: 10.1182/asheducation-2013.1.601. Review.

8.

Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.

Sison EA, McIntyre E, Magoon D, Brown P.

Mol Cancer Res. 2013 Sep;11(9):1004-16. doi: 10.1158/1541-7786.MCR-13-0114. Epub 2013 Jun 10.

9.

MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.

Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P.

Br J Haematol. 2013 Mar;160(6):785-97. doi: 10.1111/bjh.12205. Epub 2013 Jan 7.

10.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

11.

The bone marrow microenvironment and leukemia: biology and therapeutic targeting.

Sison EA, Brown P.

Expert Rev Hematol. 2011 Jun;4(3):271-83. doi: 10.1586/ehm.11.30. Review.

Supplemental Content

Loading ...
Support Center